Overview

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status:
Completed

Trial end date:
2019-02-09

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well cabozantinib-s-malate works in treating patients with ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back or is growing, spreading, or getting worse. Cabozantinib-s-malate may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth and also by blocking some of the enzymes needed for cell growth.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Collaborator:

NRG Oncology